FDA
-
-
-
-
-
-
-
Can-Fite: Positive New Data from it’s Phase III Psoriasis Study will be Presented Today at an Industry Expert Summit in Boston
-
-
-
-
-
-
-
Can-Fite BioPharma (CANF) Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through its Partner Vetbiolix
-
-
-
-
-
-
-
Can-Fite Announces Publication of Clinical Study Data for Piclidenoson and Namodenoson in Scientific Journal
-
-
-
-
-
-
-
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
-
-
-
-
-
-
-
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
-
-
-
-
-
-
-
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
-
-
-
-
-
-
-
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
-
251,657 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All